An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats

References

• RD Plattner, PE Nelson. Production of beauvericin by a strain of Fusarium proliferatum isolated from Corn Fodder for Swine. Appl Environ Microbiol 1994;60:3894–3896.
   PubMed Web of Science ®Google Scholar
• LX Zhang, KZ Yan, Y Zhang, R Huang, J Bian, CS Zheng, HX Sun, ZH Chen, N Sun, R An, FG Min, WB Zhao, Y Zhuo, JL You, YJ Song, ZY Yu, ZH Liu, KQ Yang, H Gao, HQ Dai, XL Zhang, J Wang, CZ Fu, G Pei, JT Liu, S Zhang, G Michael, YY Jiang, J Kuai, GC Zhou, XP Chen. High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. PNAS 2007;104:4606–4611.
   PubMed Web of Science ®Google Scholar
• JL Goodman, DJ Winston, RA Greenfield, PH Chandrasekar, B Fox, H Kaizer, RK Shadduck, TC Shea, P Stiff, DJ Friedman. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845–851.
   PubMed Web of Science ®Google Scholar
• MT Larocco, SJ Burgert. Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. Clin Microbiol Rev 1997;10:277–297.
   PubMed Web of Science ®Google Scholar
• V Sanchez, JA Vasquez, D Barth-Jones, L Dembry, JD Sobel, MJ Zervus. Nosocomial acquisition of Candida parapsilosis: An epidemiologic study. Am J Med 1993;94:577–582.
   PubMed Web of Science ®Google Scholar
• JH Rex, MG Rinaldi, MA Pfaller. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1–8.
   PubMed Web of Science ®Google Scholar
• MA Ghannoum, LB Rice. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501–517.
   PubMed Web of Science ®Google Scholar
• AM Sugar, SG Alsip, JN Galgiani, JR Graybill, WE Dismukes, GA Cloud, PC Craven, DA Stevens. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1997;31:1874–1878.
   Web of Science ®Google Scholar
• TD Bjornsson, JT Callaghan, HJ Einolf, V Fischer, L Gan, S Grimm, J Kao, PS King, G Miwa, L Ni, G Kumar, J Mcleod, SR Obach, S Roberts, A Roe, A Shah, F Snikeris, JT Sullivan, D Tweedie, JM Vega, J Walsh, SA Wrighton. The conduct of in vitro and in vivo drug-drug interaction studies: A pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815–832.
   PubMed Web of Science ®Google Scholar
• CL Crespi, DM Stresser. Fluorometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Meth 2000;44:325–331.
   PubMed Web of Science ®Google Scholar
• ZL Xia, JY Ying, R Sheng, S Zeng, YZ Hu, TW Yao. In vitro metabolism of BYZX in human liver microsomes and the structural elucidation of metabolite by liquid chromatography–mass spectrometry method. J Chromatogr B 2007;857:266–274.
   PubMed Web of Science ®Google Scholar
• M Yao, MS Zhu, WS Michael, HJ Zhang, WG Humphreys, AD Rodrigues, R Dai. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC–MS/MS analysis. J Pharm Biomed Anal 2007;44:211–223.
   PubMed Web of Science ®Google Scholar
• DF Zhong, SQ Zhang, L Sun, XY Zhao. Metabolism of roxithromycin in phenobarbital-treated rat liver microsomes. Acta Pharmacol Sin 2002;23:455–460.
   PubMed Web of Science ®Google Scholar
• OH Lowry, NJ Rosebrough, AL Farr, RJ Randall. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
   PubMed Web of Science ®Google Scholar
• K Kobayashi, K Urashima, N Shimada, K Chiba. Substrate specificity for rat cytochrome P450 (CYP) isoforms: Screening with cDNA-expressed systems of the rat. Biochem Pharmacol 2002;63:889–896.
   PubMed Web of Science ®Google Scholar
• SR Obach, AE Reed-Hagen. Measurement of Michaelis Constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 2002;30:831–837.
   PubMed Web of Science ®Google Scholar
• A Nath, WM Atkins. A theoretical validation of the substrate depletion approach to determining kinetic parameters. Drug Metab Dispos 2006;34:1433–1435.
   PubMed Web of Science ®Google Scholar
• IH Segal. Enzyme kinetics. New York: Wiley-Interscience; 1975. p 957.
   Google Scholar
• TK Chang, J Chen, WB Lee. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: Evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 2001;299:874–882.
   PubMed Web of Science ®Google Scholar
• D Zhang, M Zhu, WG Humphreys. Drug metabolism in drug design and developmen. New Jersey: Wiley; 2007. p 513–543.
   Google Scholar
• D Rodriques. Drug-drug interactions. New York: Marcel Dekker, Inc; 2002. p 217–293.
   Google Scholar
• JS Lee, RS Obach, MB Fisher. Drug metabolizing enyzmes: Cytochrome P450 and other enzymes in drug discovery and development. New York: Fontis Media, Lausanne, Switzerland and Marcel Dekker; 2003. p 211–254.
   Google Scholar
• HM Jones, JB Houston. Substrate depletion approach for determining in vitro metabolic clearence: Time dependences in hepatocyte and microsomal incubations. Drug Metab Dispos 2004;32:973–982.
   PubMed Web of Science ®Google Scholar
• T Kotegawa, BE Laurijssens, ALB Durol, DJ Greenblatt. Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat. Biopharm Drug Dispos 1999;20:49–52.
   PubMed Web of Science ®Google Scholar